Opinion|Videos|August 15, 2023
CheckMate 9ER Trial Updates
Author(s)Rana R. McKay, MD
Centering discussion on the CheckMate 9ER trial, Dr. McKay shares perspective of recent follow-up data of nivolumab + cabozantinib in frontline advanced RCC.
Advertisement
Episodes in this series
Advertisement
Related to this article
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
2
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
3
Retlirafusp Alfa Improves Overall Survival in Phase 3 Trial of HER2– Gastric Cancer
4
Dr Beck on the Practical Realities of Subcutaneous Oncology Drug Delivery
5